Aliases & Classifications for Ureteral Obstruction

Aliases & Descriptions for Ureteral Obstruction:

Name: Ureteral Obstruction 12 52 14

External Ids:

Disease Ontology 12 DOID:5199
ICD9CM 35 593.4
SNOMED-CT 64 197807001
UMLS 69 C0029866

Summaries for Ureteral Obstruction

MalaCards based summary : Ureteral Obstruction is related to henoch-schoenlein purpura and hemorrhagic cystitis. An important gene associated with Ureteral Obstruction is TGFB1 (Transforming Growth Factor Beta 1), and among its related pathways/superpathways are PEDF Induced Signaling and TGF-Beta Pathway. The drugs Silodosin and Desflurane have been mentioned in the context of this disorder. Affiliated tissues include kidney, bone and endothelial, and related phenotypes are Increased shRNA abundance (Z-score > 2) and cardiovascular system

Related Diseases for Ureteral Obstruction

Diseases related to Ureteral Obstruction via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 127)
id Related Disease Score Top Affiliating Genes
1 henoch-schoenlein purpura 29.7 AQP2 SLC12A1 TGFB1
2 hemorrhagic cystitis 29.3 AGTR1 BMP6 BMP7 TGFB1
3 renal fibrosis 10.5
4 refractory celiac disease 10.3 IL10 TGFB1
5 pulmonary valve insufficiency 10.2 AQP2 BMP7 TGFB1
6 preaxial polydactyly of fingers 10.2 AGTR1 AGTR2 TGFB1
7 systolic heart failure 10.2 AGTR1 AGTR2 TGFB1
8 acute necrotizing encephalitis 10.2 AQP2 BMP7 PTGS2 TGFB1
9 atrophy of prostate 10.1 IL10 SLC12A1 SLC9A3
10 liver inflammatory pseudotumor 10.1 IL10 NOS2 TGFB1
11 calcinosis 10.1 AGTR1 AQP2 EPO TGFB1
12 familial nephrotic syndrome 10.1 AGTR1 EPO TGFB1
13 reactive arthritis 10.1 CTNNB1 PTGS2 TP53
14 hydronephrosis 10.1
15 retroperitoneal fibrosis 10.1
16 ideomotor apraxia 10.1 CTNNB1 PTGS2 TP53
17 advanced sleep phase syndrome 10.1 CTNNB1 PTGS2 TP53
18 paroxysmal nocturnal hemoglobinuria 10.1 CTNNB1 TGFB1 TP53
19 congenital symblepharon 10.1 CTNNB1 PTGS2 TP53
20 bile duct clear cell adenocarcinoma 10.1 PTGS2 TP53
21 collagenous colitis 10.1 CTNNB1 IL10 NOS2 PTGS2
22 mass syndrome 10.1 AGTR1 BMP6 TGFB1
23 asperger syndrome 10.0 CTNNB1 PTGS2 TP53
24 discharging ear 10.0 BMP6 IL10 TGFB1
25 oral squamous cell carcinoma 10.0 CTNNB1 PTGS2 TP53
26 in situ pulmonary adenocarcinoma 10.0 CTNNB1 PTGS2 TGFB1 TP53
27 proctitis 10.0 CTNNB1 PTGS2 TGFB1 TP53
28 anuria 10.0
29 vestibular gland benign neoplasm 10.0 CTNNB1 PTGS2 TP53
30 bone angioendothelial sarcoma 10.0 IL10 PTGS2 TGFB1
31 anterior foramen magnum meningioma 10.0 EPO IL10 TP53
32 aneurysm 10.0
33 hypertension, essential 10.0 AGTR1 AGTR2 NOS2 SLC12A1
34 vesicoureteral reflux 10.0
35 dysphagia lusoria 10.0 PTGS1 PTGS2 SLC12A1
36 pearson syndrome 10.0 CTNNB1 TGFB1 TP53
37 acute closed-angle glaucoma 10.0 PTGS1 PTGS2 TGFB1
38 endometriosis 9.9
39 detrusor sphincter dyssynergia 9.9 IL10 NOS2 TGFB1
40 bladder signet ring cell adenocarcinoma 9.9 IL10 PTGS1 PTGS2
41 childhood central nervous system mixed germ cell tumor 9.9 IL10 PTGS1 PTGS2
42 lipomatosis 9.9
43 pelvic lipomatosis 9.9
44 endotheliitis 9.9
45 hyperornithinemia-hyperammonemia-homocitrullinemia syndrome 9.9 PTGS1 PTGS2 TP53
46 bare lymphocyte syndrome, type i 9.9 IL10 NOS2 PTGS1 PTGS2
47 pyelonephritis 9.9
48 aortic aneurysm 9.9
49 respiratory system disease 9.8 IL10 PTGS1 PTGS2
50 prostatitis 9.8

Graphical network of the top 20 diseases related to Ureteral Obstruction:



Diseases related to Ureteral Obstruction

Symptoms & Phenotypes for Ureteral Obstruction

GenomeRNAi Phenotypes related to Ureteral Obstruction according to GeneCards Suite gene sharing:

26
id Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Increased shRNA abundance (Z-score > 2) GR00366-A-100 9.92 BMP7 IL10
2 Increased shRNA abundance (Z-score > 2) GR00366-A-105 9.92 PTGS1 TGFB1
3 Increased shRNA abundance (Z-score > 2) GR00366-A-11 9.92 BMP7
4 Increased shRNA abundance (Z-score > 2) GR00366-A-113 9.92 IL10
5 Increased shRNA abundance (Z-score > 2) GR00366-A-120 9.92 TGFB1
6 Increased shRNA abundance (Z-score > 2) GR00366-A-121 9.92 PTGS1
7 Increased shRNA abundance (Z-score > 2) GR00366-A-125 9.92 IL10
8 Increased shRNA abundance (Z-score > 2) GR00366-A-128 9.92 IL10
9 Increased shRNA abundance (Z-score > 2) GR00366-A-132 9.92 IL10
10 Increased shRNA abundance (Z-score > 2) GR00366-A-137 9.92 PTGS1 BMP7
11 Increased shRNA abundance (Z-score > 2) GR00366-A-140 9.92 TGFB1
12 Increased shRNA abundance (Z-score > 2) GR00366-A-143 9.92 TGFB1
13 Increased shRNA abundance (Z-score > 2) GR00366-A-152 9.92 IL10
14 Increased shRNA abundance (Z-score > 2) GR00366-A-161 9.92 IL10
15 Increased shRNA abundance (Z-score > 2) GR00366-A-169 9.92 TGFB1 PTGS1
16 Increased shRNA abundance (Z-score > 2) GR00366-A-177 9.92 BMP7
17 Increased shRNA abundance (Z-score > 2) GR00366-A-178 9.92 TGFB1
18 Increased shRNA abundance (Z-score > 2) GR00366-A-198 9.92 TGFB1 BMP7 IL10 PTGS1
19 Increased shRNA abundance (Z-score > 2) GR00366-A-210 9.92 IL10
20 Increased shRNA abundance (Z-score > 2) GR00366-A-214 9.92 IL10
21 Increased shRNA abundance (Z-score > 2) GR00366-A-25 9.92 IL10
22 Increased shRNA abundance (Z-score > 2) GR00366-A-35 9.92 TGFB1
23 Increased shRNA abundance (Z-score > 2) GR00366-A-52 9.92 BMP7 IL10
24 Increased shRNA abundance (Z-score > 2) GR00366-A-56 9.92 TGFB1
25 Increased shRNA abundance (Z-score > 2) GR00366-A-67 9.92 IL10
26 Increased shRNA abundance (Z-score > 2) GR00366-A-74 9.92 BMP7
27 Increased shRNA abundance (Z-score > 2) GR00366-A-78 9.92 BMP7
28 Increased shRNA abundance (Z-score > 2) GR00366-A-80 9.92 IL10
29 Increased shRNA abundance (Z-score > 2) GR00366-A-82 9.92 IL10
30 Increased shRNA abundance (Z-score > 2) GR00366-A-83 9.92 BMP7
31 Increased shRNA abundance (Z-score > 2) GR00366-A-85 9.92 IL10
32 Increased shRNA abundance (Z-score > 2) GR00366-A-96 9.92 BMP7

MGI Mouse Phenotypes related to Ureteral Obstruction:

44 (show all 20)
id Description MGI Source Accession Score Top Affiliating Genes
1 cardiovascular system MP:0005385 10.42 AGTR1 AGTR2 BMP7 CLU CTNNB1 EPO
2 behavior/neurological MP:0005386 10.4 PTGS1 PTGS2 SLC12A1 TGFB1 TP53 AGTR1
3 homeostasis/metabolism MP:0005376 10.39 AGTR1 AGTR2 AQP2 CLU CTNNB1 EPO
4 growth/size/body region MP:0005378 10.38 AGTR1 IL10 NOS2 PTGS1 PTGS2 SLC12A1
5 hematopoietic system MP:0005397 10.34 AGTR1 AQP2 BMP7 CTNNB1 EPO HSPB1
6 immune system MP:0005387 10.31 AGTR1 BMP7 CLU CTNNB1 EPO HSPB1
7 cellular MP:0005384 10.27 TGFB1 TP53 AGTR2 CTNNB1 EPO HSPB1
8 digestive/alimentary MP:0005381 10.26 AGTR2 BMP7 CTNNB1 IL10 NOS2 PTGS1
9 integument MP:0010771 10.26 NOS2 PTGS1 PTGS2 SLC12A1 TGFB1 TP53
10 endocrine/exocrine gland MP:0005379 10.25 PTGS2 SLC9A3 TGFB1 TP53 AGTR2 BMP7
11 mortality/aging MP:0010768 10.25 AGTR1 AGTR2 AQP2 BMP7 CTNNB1 EPO
12 adipose tissue MP:0005375 10.14 AGTR1 AGTR2 NOS2 PTGS2 SLC9A3 TGFB1
13 muscle MP:0005369 10.1 CLU CTNNB1 EPO IL10 NOS2 PTGS1
14 renal/urinary system MP:0005367 10.07 CLU CTNNB1 NOS2 PTGS1 PTGS2 SLC12A1
15 nervous system MP:0003631 10.06 IL10 NOS2 PTGS1 PTGS2 TGFB1 TP53
16 liver/biliary system MP:0005370 10 CTNNB1 EPO IL10 NOS2 PTGS2 TGFB1
17 neoplasm MP:0002006 9.97 AGTR2 CTNNB1 IL10 NOS2 PTGS1 PTGS2
18 reproductive system MP:0005389 9.93 AQP2 BMP6 BMP7 CTNNB1 IL10 NOS2
19 respiratory system MP:0005388 9.61 BMP7 CTNNB1 EPO IL10 NOS2 PTGS1
20 skeleton MP:0005390 9.4 TGFB1 TP53 IL10 NOS2 PTGS1 PTGS2

Drugs & Therapeutics for Ureteral Obstruction

Drugs for Ureteral Obstruction (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 66)
id Name Status Phase Clinical Trials Cas Number PubChem Id
1
Silodosin Approved Phase 4 160970-54-7
2
Desflurane Approved Phase 4 57041-67-5 42113
3
Isoflurane Approved, Vet_approved Phase 4 26675-46-7 3763
4
Sevoflurane Approved, Vet_approved Phase 4 28523-86-6 5206
5
Tamsulosin Approved, Investigational Phase 4,Phase 3 106133-20-4 129211
6
Acetaminophen Approved Phase 4 103-90-2 1983
7
Mirabegron Approved Phase 4,Phase 2 223673-61-8
8 Adrenergic Agents Phase 4,Phase 3,Phase 2
9 Adrenergic alpha-1 Receptor Antagonists Phase 4,Phase 3
10 Adrenergic alpha-Antagonists Phase 4,Phase 3
11 Adrenergic Antagonists Phase 4,Phase 3
12 Neurotransmitter Agents Phase 4,Phase 3,Phase 2
13 Anesthetics Phase 4,Phase 2
14 Anesthetics, General Phase 4
15 Anesthetics, Inhalation Phase 4
16 Central Nervous System Depressants Phase 4,Phase 2
17 Platelet Aggregation Inhibitors Phase 4
18 Peripheral Nervous System Agents Phase 4,Phase 2
19 Acetaminophen, hydrocodone drug combination Phase 4
20 Adrenergic Agonists Phase 4,Phase 2
21 Adrenergic beta-3 Receptor Agonists Phase 4,Phase 2
22 Adrenergic beta-Agonists Phase 4,Phase 2
23 Analgesics Phase 4
24 Analgesics, Non-Narcotic Phase 4
25 Antipyretics Phase 4
26 Narcotics Phase 4
27 Cholinergic Agents Phase 4
28 Cholinergic Antagonists Phase 4
29 Muscarinic Antagonists Phase 4
30 Tolterodine tartrate Phase 4 124937-52-6
31 Calcium, Dietary Phase 4
32
Triclosan Approved Phase 2 3380-34-5 5564
33
Lidocaine Approved, Vet_approved Phase 2 137-58-6 3676
34
Gemcitabine Approved Phase 2,Phase 1 95058-81-4 60750
35
Paclitaxel Approved, Vet_approved Phase 2 33069-62-4 36314
36 Anti-Infective Agents Phase 2,Phase 1
37 Anti-Infective Agents, Local Phase 2
38 Antimetabolites Phase 2,Phase 1
39 Hypolipidemic Agents Phase 2
40
Iodine Phase 2 7553-56-2 807
41 Lipid Regulating Agents Phase 2
42 Anesthetics, Local Phase 2
43 Anti-Arrhythmia Agents Phase 2
44 Diuretics, Potassium Sparing Phase 2
45 Sodium Channel Blockers Phase 2
46 Antibodies Phase 2,Phase 1
47 Antibodies, Monoclonal Phase 2,Phase 1
48 Immunoglobulins Phase 2,Phase 1
49 Albumin-Bound Paclitaxel Phase 2
50 Antimetabolites, Antineoplastic Phase 2,Phase 1

Interventional clinical trials:

(show all 48)
id Name Status NCT ID Phase
1 Efficacy and Safety of a Covered Self-expandable Dual-layered Metallic Mesh Stent (UVENTA) in Ureteral Obstruction Unknown status NCT01788865 Phase 4
2 Functional MR Urography Completed NCT00301470 Phase 4
3 Efficacy and Safety of Silodosin in the Treatment of Natural Expulsion in Patients With Ureteral Stones Completed NCT01533389 Phase 4
4 Recovery Following Desflurane Versus Sevoflurane for Outpatient Urologic Surgery in Elderly Females Completed NCT01310582 Phase 4
5 Ureteral Stent-related Pain and Mirabegron (SPAM) Trial Recruiting NCT02095665 Phase 4
6 Treatment of Symptoms After Stent Placement for Urinary Tract Obstruction Active, not recruiting NCT01741454 Phase 4
7 Clinical Study of the Aorta-femoral Bypass and Hybrid Intervention and the Iliac Arteries With Stenting and Plasty of the Common Femoral Artery Effectiveness in Patients With the Iliac Segment and Femoral Artery Occlusive Disease (TASC C, D) Active, not recruiting NCT02580084 Phase 4
8 Evaluation of the Efficacy of Tamsulosin (Alpha Blockers) Compared to Phloroglucinol in Improving JJ Ureteral Stent Tolerance. A Randomized Controlled Trial Completed NCT01061073 Phase 3
9 Radical Versus Simple Hysterectomy and Pelvic Node Dissection in Patients With Low-risk Early Stage Cervical Cancer (SHAPE) Recruiting NCT01658930 Phase 3
10 Use of Alfuzosin in Stone Treatment With ESWL Withdrawn NCT00388271 Phase 3
11 Comparison of Silicone-covered Metallic Ureteral Stent and Double-J Stent for Malignant Ureteral Obstruction Unknown status NCT01823575 Phase 2
12 Tolerance and Effectiveness of Ureteral Stents MEMOKATH ® 051 in Chronic Strictures of the Ureter Completed NCT00790686 Phase 2
13 Assessment of Drug-eluting Ureteral Stent on Bacterial Adherence and Biofilm Formation Completed NCT00250406 Phase 2
14 A Randomized Control Trial Comparing Single vs. Multiple Application of Lidocaine Analgesia Prior to Urethral Catheterization Procedures Completed NCT00142064 Phase 2
15 Randomized Controlled Trial of Cystocele Plication Risks ("CPR Trial"): A Pilot Study Completed NCT01197248 Phase 2
16 TRC105 in Adults With Advanced/Metastatic Urothelial Carcinoma Completed NCT01328574 Phase 2
17 Study of Genexol-PM in Patients With Advanced Urothelial Cancer Previously Treated With Gemcitabine and Platinum Completed NCT01426126 Phase 2
18 Mirabegron as Medical Expulsive Therapy (MET) for Ureteral Stones and Ureteral Stent Pain Not yet recruiting NCT02744430 Phase 2
19 Assessment of Gemcitabine as Chemoradiotherapy in Patients With Locally Advanced Carcinoma of Cervix and Renal Disease Not yet recruiting NCT03101995 Phase 2
20 Pembrolizumab and Docetaxel or Gemcitabine Hydrochloride in Treating Patients Urothelial Cancer Recruiting NCT02437370 Phase 1
21 Cabozantinib-s-malate and Nivolumab With or Without Ipilimumab in Treating Patients With Metastatic Genitourinary Tumors Recruiting NCT02496208 Phase 1
22 Ureteral Reimplantation for the Treatment of Extrinsic Malignant Ureteral Obstruction Unknown status NCT02160652
23 The Correlation Between Renal Injury and Biomarkers in Pediatric Ureteropelvic Junction Obstruction Patients Unknown status NCT01711996
24 Ureteropelvic Junction Obstruction in Early Childhood: Comparison of Surgical Therapy and Surveillance. A Prospective, Randomized, Controlled Multi-Center Study Unknown status NCT00444431
25 A Prospective Comparison Between Ureteral Stent and Nephrostomy Tube for an Urgent Drainage of Obstructed Kidney Unknown status NCT00739284
26 Drainage of Malignant Extrinsic Ureteral Obstruction Using the Memokath Ureteral Stent Completed NCT00166361
27 Urinary Biomarkers as Predictors on Renal Function in Congenital Hydronephrosis Completed NCT00568724
28 Laparoscopic Pyeloplasty Registry and Database Completed NCT00169650
29 Evaluating Ureteral Length Using Computed Tomography (CT) Completed NCT01542593
30 The Efficacy and Safety of Local Anesthetic Infusion With Ropivacaine Completed NCT00930046
31 Dismembered Pyeloplasty With and Without After Coming Stent Completed NCT02138877
32 Uretal Flow Assessment During Gynecological Procedures Completed NCT00453882
33 Urinary Markers for Unilateral Kidney Obstruction Completed NCT01979042
34 Comparison of Two Position for Ultrasound Guided Lumbar Plexus and Sciatic Nerve Block Completed NCT00988234
35 Clinical Significance of Supranormal Differential Renal Function in the Recovery of Hydronephrosis Completed NCT01839006
36 Early Infancy Ureteral Reimplantation for Distal Ureteral Obstruction Recruiting NCT02419339
37 Indwelling Double-J Ureteral Stent Versus Externalized Modified-Salle Stent for Pyeloplasty Recruiting NCT02713633
38 Multi-Center Comparison of Dual Lumen Versus Single Lumen Ureteroscopes Recruiting NCT02123082
39 Randomized Trial of NSAID vs Placebo Prior to Ureteral Stent Removal Recruiting NCT02140970
40 Indwelling Stent Discoloration Project Recruiting NCT02007980
41 Percutaneous Nephrostomy Versus Stent In Sepsis Trial Recruiting NCT02929160
42 Care of the Urothelial Cancer Patient and Prospective Procurement of Urothelial Cancer Tissue Recruiting NCT02379429
43 Diagnostic Relevance of Laser Confocal Microscopy for the Screening of Upper Urinary Tract Tumors Active, not recruiting NCT02276924
44 UC-GENOME: Urothelial Cancer-GENOmic Analysis to iMprove Patient Outcomes and rEsearch Active, not recruiting NCT02643043
45 CTT on Renogram as an Early Marker of Significant Obstruction in Uretero-pelvic Junction Syndrome Not yet recruiting NCT02812212
46 Comparison of Dynamic Contrast Enhanced CT and Diuretic Renogram in The Evaluation of UPJO Terminated NCT00199472
47 Study to Determine if There Are Specific Clinical Factors to Determine Stent Encrustation Terminated NCT00581178
48 Severe Pelvic Organ Prolapse and Post-Obstructive Diuresis (SOPPO) Pilot Study Withdrawn NCT02060331

Search NIH Clinical Center for Ureteral Obstruction

Genetic Tests for Ureteral Obstruction

Anatomical Context for Ureteral Obstruction

MalaCards organs/tissues related to Ureteral Obstruction:

39
Kidney, Bone, Endothelial, Monocytes, Bone Marrow, Colon, Prostate

Publications for Ureteral Obstruction

Articles related to Ureteral Obstruction:

(show top 50) (show all 673)
id Title Authors Year
1
Renal recruitment of B lymphocytes exacerbates tubulointerstitial fibrosis by promoting monocyte mobilization and infiltration after unilateral ureteral obstruction. ( 27763657 )
2017
2
Deficiency of mPGES-1 exacerbates renal fibrosis and inflammation in mice with unilateral ureteral obstruction. ( 27784694 )
2017
3
Downregulation of angiotensin type 1 receptor and nuclear factor-I_B by sirtuin 1 contributes to renoprotection in unilateral ureteral obstruction. ( 27659793 )
2016
4
Regulation of eIF2I+ expression and renal interstitial fibrosis by resveratrol in rat renal tissue after unilateral ureteral obstruction. ( 26923138 )
2016
5
Effects of exendin-4 on the intrarenal renin-angiotensin system and interstitial fibrosis in unilateral ureteral obstruction mice: Exendin-4 and unilateral ureteral obstruction. ( 27913661 )
2016
6
Sorafenib Inhibits Renal Fibrosis Induced by Unilateral Ureteral Obstruction via Inhibition of Macrophage Infiltration. ( 27744426 )
2016
7
Involvement of spliced X-box binding protein 1 in renal fibrosis induced by unilateral ureteral obstruction in mice. ( 27108902 )
2016
8
CD39 overexpression does not attenuate renal fibrosis in the unilateral ureteric obstructive model of chronic kidney disease. ( 27565966 )
2016
9
Delayed-onset Ureteral Obstruction and Calcification Masquerading as Renal Colic Following Deflux Injection. ( 26970448 )
2016
10
Breviscapine prevents downregulation of renal water and sodium transport proteins in response to unilateral ureteral obstruction. ( 27403265 )
2016
11
Interferon gamma peptidomimetic targeted to interstitial myofibroblasts attenuates renal fibrosis after unilateral ureteral obstruction in mice. ( 27509062 )
2016
12
Predicting the failure of retrograde ureteral stent insertion for managing malignant ureteral obstruction in outpatients. ( 26870299 )
2016
13
Melatonin protects kidney against apoptosis induced by acute unilateral ureteral obstruction in rats. ( 27551563 )
2016
14
Placement of subcutaneous ureteral bypasses without fluoroscopic guidance in cats with ureteral obstruction: 19 cases (2014-2016). ( 27694368 )
2016
15
Piceatannol Attenuates Renal Fibrosis Induced by Unilateral Ureteral Obstruction via Downregulation of Histone Deacetylase 4/5 or p38-MAPK Signaling. ( 27902771 )
2016
16
Improving Comfort of Patients with Ureteral Obstruction and Malignant Disease Should Be of Concern. ( 27387032 )
2016
17
The Protective Effect of Melittin on Renal Fibrosis in an Animal Model of Unilateral Ureteral Obstruction. ( 27618890 )
2016
18
T-type calcium channel blocker attenuates unilateral ureteral obstruction-induced renal interstitial fibrosis by activating the Nrf2 antioxidant pathway. ( 27904663 )
2016
19
CD11ca8_ CD8a8_ T Cells Reduce Renal Fibrosis Following Ureteric Obstruction by Inducing Fibroblast Apoptosis. ( 28025478 )
2016
20
Kidney Tissue Targeted Metabolic Profiling of Unilateral Ureteral Obstruction Rats by NMR. ( 27695416 )
2016
21
Mesenchymal Stromal Cells Prevent Renal Fibrosis in a Rat Model of Unilateral Ureteral Obstruction by Suppressing the Renin-Angiotensin System via HuR. ( 26866372 )
2016
22
The effect of aliskiren on the renal dysfunction following unilateral ureteral obstruction in the rat. ( 27570581 )
2016
23
Persistent activation of autophagy in kidney tubular cells promotes renal interstitial fibrosis during unilateral ureteral obstruction. ( 27123926 )
2016
24
Screening and identification of the differentially expressed proteins in neonatal rat kidney after partial unilateral ureteral obstruction. ( 27222353 )
2016
25
Taking the STING Out of Ureteral Obstruction. ( 27785466 )
2016
26
Cells of renin lineage express hypoxia inducible factor 2I+ following experimental ureteral obstruction. ( 26746687 )
2016
27
Protective role of propofol on the kidney during early unilateral ureteral obstruction through inhibition of epithelial-mesenchymal transition. ( 27158339 )
2016
28
A porcine model of relief of unilateral ureteral obstruction: study on self-repairing capability over multiple time points. ( 27381184 )
2016
29
Abdominal pain and hematuria: duodenal perforation from ingested foreign body causing ureteral obstruction and hydronephrosis. ( 26903557 )
2016
30
Ureteral obstruction secondary to disseminated penicilliosis in a German shepherd dog. ( 27928169 )
2016
31
The study on serum and urine of renal interstitial fibrosis rats induced by unilateral ureteral obstruction based on metabonomics and network analysis methods. ( 26873208 )
2016
32
Metformin Prevents Renal Fibrosis in Mice with Unilateral Ureteral Obstruction and Inhibits Ang II-Induced ECM Production in Renal Fibroblasts. ( 26805826 )
2016
33
Use of Corticosteroids for Urinary Tuberculosis Patients at Risk of Developing Ureteral Obstruction. ( 27904125 )
2016
34
Renal pelvic and ureteral ultrasonographic characteristics of cats with chronic kidney disease in comparison with normal cats, and cats with pyelonephritis or ureteral obstruction. ( 27389573 )
2016
35
Outcomes of patients with ureteral obstruction who achieved stent-free state following balloon dilatation. ( 27603427 )
2016
36
Overexpression of the short endoglin isoform reduces renal fibrosis and inflammation after unilateral ureteral obstruction. ( 27321931 )
2016
37
Lipopolysaccharide-induced inflammation or unilateral ureteral obstruction yielded multiple types of glycosylated Lipocalin 2. ( 26949374 )
2016
38
Peroxisome proliferator-activated receptor-I^ agonist pioglitazone fails to attenuate renal fibrosis caused by unilateral ureteral obstruction in mice. ( 26838738 )
2016
39
Use of intravoxel incoherent motion MRI to assess renal fibrosis in a rat model of unilateral ureteral obstruction. ( 26841951 )
2016
40
Carnosic acid attenuates unilateral ureteral obstruction-induced kidney fibrosis via inhibition of Akt-mediated Nox4 expression. ( 27212017 )
2016
41
Metabolomics study of renal fibrosis and intervention effects of total aglycone extracts of Scutellaria baicalensis in unilateral ureteral obstruction rats. ( 27286917 )
2016
42
Danggui Buxue Tang Attenuates Tubulointerstitial Fibrosis via Suppressing NLRP3 Inflammasome in a Rat Model of Unilateral Ureteral Obstruction. ( 27872860 )
2016
43
Elsholtzia ciliata (Thunb.) Hylander attenuates renal inflammation and interstitial fibrosis via regulation of TGF-A9 and Smad3 expression on unilateral ureteral obstruction rat model. ( 27002403 )
2016
44
A Curious Case of Ureteral Obstruction in a 15-Year-Old Female. ( 27449991 )
2016
45
Nitric oxide and asymmetric dimethyl arginine (ADMA) levels in an experimental hydronephrotic kidney caused by unilateral partial ureteral obstruction. ( 27286129 )
2016
46
Brd4 inhibition attenuates unilateral ureteral obstruction-induced fibrosis by blocking TGF-I^-mediated Nox4 expression. ( 28063381 )
2016
47
Artesunate attenuates unilateral ureteral obstruction-induced renal fibrosis by regulating the expressions of bone morphogenetic protein-7 and uterine sensitization-associated gene-1 in rats. ( 26865179 )
2016
48
SREBP inhibition ameliorates renal injury after unilateral ureteral obstruction. ( 27385736 )
2016
49
Use of percutaneous nephrostomy and ureteral stenting in management of ureteral obstruction. ( 26981442 )
2016
50
A high affinity kidney targeting by chitobionic acid-conjugated polysorbitol gene transporter alleviates unilateral ureteral obstruction in rats. ( 27318934 )
2016

Variations for Ureteral Obstruction

Expression for Ureteral Obstruction

Search GEO for disease gene expression data for Ureteral Obstruction.

Pathways for Ureteral Obstruction

Pathways related to Ureteral Obstruction according to GeneCards Suite gene sharing:

(show all 27)
id Super pathways Score Top Affiliating Genes
1
Show member pathways
13.54 BMP6 BMP7 EPO IL10 NOS2 PTGS1
2
Show member pathways
13.4 AGTR1 AGTR2 BMP6 BMP7 EPO HSPB1
3
Show member pathways
12.94 AGTR1 AGTR2 BMP6 BMP7 PTGS2 TGFB1
4 12.48 AGTR1 CTNNB1 NOS2 PTGS2 TGFB1 TP53
5
Show member pathways
12.45 AGTR1 CTNNB1 IL10 NOS2 TP53
6
Show member pathways
12.25 CTNNB1 HSPB1 NOS2 PTGS1 PTGS2
7
Show member pathways
12.14 IL10 NOS2 PTGS2 TGFB1
8 12.12 BMP6 BMP7 CTNNB1 TGFB1
9 12.02 BMP6 BMP7 CTNNB1 TGFB1
10 11.98 CTNNB1 NOS2 PTGS2 TGFB1 TP53
11 11.87 NOS2 PTGS2 TGFB1 TP53
12 11.79 BMP6 BMP7 TGFB1
13 11.72 NOS2 PTGS2 TP53
14 11.72 BMP6 BMP7 TGFB1
15 11.72 HSPB1 IL10 NOS2 TGFB1
16 11.71 IL10 NOS2 PTGS2 TGFB1 TP53
17
Show member pathways
11.69 AGTR1 AGTR2 TGFB1
18 11.63 IL10 NOS2 TGFB1
19 11.6 AGTR1 EPO IL10
20 11.58 BMP6 BMP7 TGFB1
21 11.52 CTNNB1 PTGS1 PTGS2
22 11.33 NOS2 PTGS2 TGFB1 TP53
23 11.1 NOS2 PTGS1 PTGS2
24 11.02 EPO NOS2 PTGS2 TP53
25 10.83 BMP6 BMP7 CTNNB1 HSPB1 TGFB1 TP53
26 10.81 PTGS1 PTGS2
27 10.8 HSPB1 NOS2 PTGS2 TP53

GO Terms for Ureteral Obstruction

Cellular components related to Ureteral Obstruction according to GeneCards Suite gene sharing:

id Name GO ID Score Top Affiliating Genes
1 extracellular space GO:0005615 9.17 BMP6 BMP7 CLU EPO HSPB1 IL10

Biological processes related to Ureteral Obstruction according to GeneCards Suite gene sharing:

(show all 39)
id Name GO ID Score Top Affiliating Genes
1 positive regulation of apoptotic process GO:0043065 9.91 BMP7 CTNNB1 PTGS2 TGFB1 TP53
2 response to lipopolysaccharide GO:0032496 9.9 EPO IL10 NOS2 PTGS2
3 aging GO:0007568 9.87 EPO IL10 PTGS2 TGFB1
4 cellular response to hypoxia GO:0071456 9.85 BMP7 PTGS2 TP53
5 negative regulation of cell proliferation GO:0008285 9.85 BMP7 CTNNB1 IL10 PTGS2 TGFB1 TP53
6 response to organic substance GO:0010033 9.84 IL10 PTGS2 TGFB1
7 BMP signaling pathway GO:0030509 9.84 BMP6 BMP7 TGFB1
8 positive regulation of neuron differentiation GO:0045666 9.82 BMP6 BMP7 EPO
9 cellular response to mechanical stimulus GO:0071260 9.8 BMP6 PTGS2 TGFB1
10 response to glucocorticoid GO:0051384 9.79 BMP6 IL10 PTGS2
11 regulation of blood pressure GO:0008217 9.79 AGTR2 PTGS1 PTGS2
12 negative regulation of cell death GO:0060548 9.78 BMP7 CLU CTNNB1
13 SMAD protein signal transduction GO:0060395 9.76 BMP6 BMP7 TGFB1
14 positive regulation of osteoblast differentiation GO:0045669 9.75 BMP6 BMP7 CTNNB1
15 kidney development GO:0001822 9.73 AGTR1 BMP6 BMP7 CTNNB1
16 inflammatory response GO:0006954 9.73 AGTR2 BMP6 IL10 PTGS1 PTGS2 TGFB1
17 positive regulation of pathway-restricted SMAD protein phosphorylation GO:0010862 9.72 BMP6 BMP7 TGFB1
18 positive regulation of nitric oxide biosynthetic process GO:0045429 9.71 AGTR2 CLU PTGS2
19 response to estradiol GO:0032355 9.71 BMP7 CTNNB1 PTGS2 TGFB1
20 positive regulation of transcription, DNA-templated GO:0045893 9.7 AGTR2 BMP7 CTNNB1 EPO IL10 TGFB1
21 prostaglandin biosynthetic process GO:0001516 9.68 PTGS1 PTGS2
22 negative regulation of blood vessel endothelial cell migration GO:0043537 9.67 AGTR2 TGFB1
23 regulation of vasodilation GO:0042312 9.67 AGTR1 AGTR2
24 negative regulation of cell cycle GO:0045786 9.67 BMP7 PTGS2 TGFB1
25 cyclooxygenase pathway GO:0019371 9.66 PTGS1 PTGS2
26 positive regulation of heterotypic cell-cell adhesion GO:0034116 9.65 BMP7 IL10
27 positive regulation of SMAD protein import into nucleus GO:0060391 9.65 BMP6 TGFB1
28 epithelial to mesenchymal transition GO:0001837 9.65 BMP7 CTNNB1 TGFB1
29 positive regulation of endothelial cell differentiation GO:0045603 9.64 BMP6 CTNNB1
30 positive regulation of histone deacetylation GO:0031065 9.64 TGFB1 TP53
31 positive regulation of bone mineralization GO:0030501 9.63 BMP6 BMP7 TGFB1
32 salivary gland morphogenesis GO:0007435 9.62 BMP7 TGFB1
33 angiotensin-activated signaling pathway GO:0038166 9.59 AGTR1 AGTR2
34 negative regulation of intrinsic apoptotic signaling pathway in response to osmotic stress GO:1902219 9.56 EPO PTGS2
35 renin-angiotensin regulation of aldosterone production GO:0002018 9.52 AGTR1 AGTR2
36 response to vitamin D GO:0033280 9.5 BMP7 PTGS2 TGFB1
37 regulation of apoptotic process GO:0042981 9.43 AGTR2 BMP6 BMP7 CTNNB1 TGFB1 TP53
38 regulation of cell proliferation GO:0042127 9.1 AGTR1 CTNNB1 NOS2 PTGS1 PTGS2 TGFB1
39 positive regulation of cell proliferation GO:0008284 10.03 AGTR2 CTNNB1 EPO PTGS2 TGFB1

Molecular functions related to Ureteral Obstruction according to GeneCards Suite gene sharing:

id Name GO ID Score Top Affiliating Genes
1 protein heterodimerization activity GO:0046982 9.8 AGTR1 BMP6 CTNNB1 TGFB1 TP53
2 cytokine activity GO:0005125 9.62 BMP6 BMP7 IL10 TGFB1
3 growth factor activity GO:0008083 9.56 BMP6 BMP7 IL10 TGFB1
4 BMP receptor binding GO:0070700 9.37 BMP6 BMP7
5 transforming growth factor beta receptor binding GO:0005160 9.33 BMP6 BMP7 TGFB1
6 angiotensin type II receptor activity GO:0004945 8.96 AGTR1 AGTR2
7 prostaglandin-endoperoxide synthase activity GO:0004666 8.62 PTGS1 PTGS2

Sources for Ureteral Obstruction

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
16 ExPASy
18 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 MedGen
42 MeSH
43 MESH via Orphanet
44 MGI
46 NCI
47 NCIt
48 NDF-RT
51 NINDS
52 Novoseek
54 OMIM
55 OMIM via Orphanet
59 PubMed
60 QIAGEN
65 SNOMED-CT via Orphanet
67 TGDB
68 Tocris
69 UMLS
70 UMLS via Orphanet
Content
Loading form....